Akeso’s Ebdarokimab (IL-12/IL-23 dual-target monoclonal antibody) has been approved in China for moderate-severe plaque psoriasis

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.